---
title: "IPH: €30 million share offering priced, extending cash runway and funding clinical pipeline"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295932428.md"
description: "A €30 million share offering was priced at €1.70 per share, resulting in 18.76% dilution and extending the cash runway through Q1 2028 with Sobi partnership proceeds. Proceeds will fund clinical and preclinical development, with shares admitted to Euronext Paris.Original document: Innate Pharma SA Class A [IPH] Press release — Aug. 14 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source."
datetime: "2026-08-14T12:05:06.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295932428.md)
  - [en](https://longbridge.com/en/news/295932428.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295932428.md)
generator: "portal-rs"
---

# IPH: €30 million share offering priced, extending cash runway and funding clinical pipeline

A €30 million share offering was priced at €1.70 per share, resulting in 18.76% dilution and extending the cash runway through Q1 2028 with Sobi partnership proceeds. Proceeds will fund clinical and preclinical development, with shares admitted to Euronext Paris.

Original document: Innate Pharma SA Class A \[IPH\] Press release — Aug. 14 2026

**Disclaimer**

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

### Related Stocks

- [IPHA.US](https://longbridge.com/en/quote/IPHA.US.md)

## Related News & Research

- [Innate Pharma prices private placement of new shares at EUR 1.7 each](https://longbridge.com/en/news/296394400.md)
- [Innate Pharma Secures €30M, Extends Cash Runway Into 2028](https://longbridge.com/en/news/295966041.md)
- [HAL: Net income fell to €856 million, but net asset value increased to €17.6 billion in H1 2026](https://longbridge.com/en/news/297209944.md)
- [Deutsche Bank Private Bank partners with Thought Machine on Vault Core platform rollout](https://longbridge.com/en/news/297144782.md)
- [LYTIX: FDA cleared pivotal Phase III trial design; R&D spending rose, equity strengthened](https://longbridge.com/en/news/297125480.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**